Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01720043 · ClinicalTrials.gov registry record · Phase 2
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01720043 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 8 participants.
The verdict
NCT01720043, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma
Interventions
- DRUG Velcade
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01720043
The ClinicalTrials.gov registry entry for NCT01720043 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Velcade is the first listed.
NCT01720043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01720043 about?
NCT01720043 is a clinical study titled "Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients". To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma
What is the current status of trial NCT01720043?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-07. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01720043?
The interventions under investigation include: Velcade (DRUG).
Who is sponsoring clinical trial NCT01720043?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.